Contributions of imprecision in PET‐MRI rigid registration to imprecision in amyloid PET SUVR measurements
暂无分享,去创建一个
Christopher G Schwarz | Matthew L Senjem | Jeffrey L Gunter | Prashanthi Vemuri | Val J Lowe | Clifford R Jack | David T. Jones | David T Jones | Ronald C Petersen | David S Knopman | C. Jack | J. Gunter | R. Petersen | P. Vemuri | M. Senjem | D. Knopman | V. Lowe | C. Schwarz
[1] R L Wahl,et al. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. , 1993, Radiology.
[2] Lennart Thurfjell,et al. Automated Quantification of 18F-Flutemetamol PET Activity for Categorizing Scans as Negative or Positive for Brain Amyloid: Concordance with Visual Image Reads , 2014, The Journal of Nuclear Medicine.
[3] Jeffrey A. Fessler,et al. Reducing between scanner differences in multi-center PET studies , 2009, NeuroImage.
[4] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[5] John Seibyl,et al. Improved longitudinal [18F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction , 2015, NeuroImage.
[6] Kengo Ito,et al. Head motion evaluation and correction for PET scans with 18F-FDG in the Japanese Alzheimer’s disease neuroimaging initiative (J-ADNI) multi-center study , 2011, Annals of Nuclear Medicine.
[7] Sébastien Ourselin,et al. PIB-PET SEGMENTATION FOR AUTOMATIC SUVR NORMALISATION WITHOUT MR INFORMATION , 2007, 2007 4th IEEE International Symposium on Biomedical Imaging: From Nano to Macro.
[8] B. Thomas. Improved brain PET quantification using partial volume correction techniques , 2012 .
[9] Mark A. Mintun,et al. A Semiautomated Method for Quantification of F 18 Florbetapir PET Images , 2015, The Journal of Nuclear Medicine.
[10] William J. Jagust,et al. Measurement of Longitudinal β-Amyloid Change with 18F-Florbetapir PET and Standardized Uptake Value Ratios , 2015, The Journal of Nuclear Medicine.
[11] J. Tukey,et al. Variations of Box Plots , 1978 .
[12] Christopher C Rowe,et al. Visual Assessment Versus Quantitative Assessment of 11C-PIB PET and 18F-FDG PET for Detection of Alzheimer's Disease , 2007, Journal of Nuclear Medicine.
[13] Clifford R. Jack,et al. Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE , 2017, NeuroImage.
[14] Karl J. Friston,et al. Unified segmentation , 2005, NeuroImage.
[15] Christer Halldin,et al. Evaluation of Two Automated Methods for PET Region of Interest Analysis , 2014, Neuroinformatics.
[16] James Robert Brašić,et al. In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18) , 2010, Journal of Nuclear Medicine.
[17] Nick C Fox,et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.
[18] E G Tangalos,et al. Prevalence of mild cognitive impairment is higher in men , 2010, Neurology.
[19] H. Kolb,et al. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease , 2013, Alzheimer's & Dementia.
[20] J O Rinne,et al. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls , 2009, Neurology.
[21] Arthur W. Toga,et al. Atlas-based whole brain white matter analysis using large deformation diffeomorphic metric mapping: Application to normal elderly and Alzheimer's disease participants , 2009, NeuroImage.
[22] Brian B. Avants,et al. Symmetric diffeomorphic image registration with cross-correlation: Evaluating automated labeling of elderly and neurodegenerative brain , 2008, Medical Image Anal..
[23] W. Jagust,et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core , 2010, Alzheimer's & Dementia.
[24] Robert A. Koeppe,et al. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET , 2015, Alzheimer's & Dementia.
[25] A. Evans,et al. Correction for partial volume effects in PET: principle and validation. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] Yun Zhou,et al. Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease , 2007, NeuroImage.
[27] Owen Carmichael,et al. Update on the Magnetic Resonance Imaging core of the Alzheimer's Disease Neuroimaging Initiative , 2010, Alzheimer's & Dementia.
[28] V. Pankratz,et al. The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample Characteristics , 2008, Neuroepidemiology.
[29] Jochen Herms,et al. Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [18F]-florbetaben PET , 2014, NeuroImage.
[30] Daniel Bandy,et al. Improved Power for Characterizing Longitudinal Amyloid-β PET Changes and Evaluating Amyloid-Modifying Treatments with a Cerebral White Matter Reference Region , 2015, The Journal of Nuclear Medicine.
[31] Olivier Salvado,et al. MR-Less Surface-Based Amyloid Assessment Based on 11C PiB PET , 2014, PloS one.
[32] Olivier Salvado,et al. MR-Less High Dimensional Spatial Normalization of 11C PiB PET Images on a Population of Elderly, Mild Cognitive Impaired and Alzheimer Disease Patients , 2008, MICCAI.
[33] C. Jack,et al. A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity , 2016, NeuroImage: Clinical.
[34] Felix Carbonell,et al. Optimal Target Region for Subject Classification on the Basis of Amyloid PET Images , 2015, The Journal of Nuclear Medicine.
[35] Robert A. Dean,et al. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients , 2016, Alzheimer's & Dementia.
[36] Lennart Thurfjell,et al. The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data , 2015, Alzheimer's & Dementia.
[37] H. Mayberg,et al. Correction of PET Data for Partial Volume Effects in Human Cerebral Cortex by MR Imaging , 1990, Journal of computer assisted tomography.
[38] C. Jack,et al. Comparison of 18F-FDG and PiB PET in Cognitive Impairment , 2009, Journal of Nuclear Medicine.
[39] C. Jack,et al. Alzheimer's Disease Neuroimaging Initiative , 2008 .
[40] P. Vemuri,et al. Brain β-amyloid load approaches a plateau , 2013, Neurology.
[41] R. Boellaard,et al. Test-retest variability of quantitative [11C]PIB studies in Alzheimer’s disease , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[42] Keith A. Johnson,et al. Partial volume correction in quantitative amyloid imaging , 2015, NeuroImage.
[43] John Seibyl,et al. Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans , 2016, The Journal of Nuclear Medicine.
[44] Paul Edison,et al. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET , 2013, NeuroImage.